Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2014

View Archived Issues

Development of a live-attenuated HIV-1 virus incapable of reactivation

Passive immunization against N-terminally truncated beta-amyloid species with NT4X-167 tested

Enrollment open in phase I study of SM-04755 in colorectal, gastric, hepatic or pancreatic cancer

Celladon in-licenses gene therapy application rights for mSCF for cardiac ischemia treatment

MetaMax initiates phase I/IIa study of MM-D37K

Shire recaps progress of second quarter 2014

Cerecor raises funds to support development of pipeline

Sorrento Therapeutics receives NCI grant for Myc inhibitor

NIBIB award supports Celsion's development of ThermoDox for brain tumors

Implantation of cells secreting NGF proves safe in Alzheimer's disease study

Cadila Healthcare discloses new PARP-1 inhibitors

Celon Pharma describes novel PDE9A inhibitors with procognitive potential

Shionogi patents novel cephems

Researchers present phase II data for ELND-005

Roche synthesizes novel COMT inhibitors

Scientists at OriBase Pharma divulge novel protein kinase inhibitors

FDA grants orphan drug status to palovarotene for FOP

European group designs new agents for viral infections

Ganetespib advances into phase III extension of AML LI-1 study

Pierre Fabre presents novel agents for schizophrenia and other disorders

Anavex Life Sciences secures cGMP manufacturing for ANAVEX 2-73

Sage Therapeutics receives fast track designation for SAGE-547

Kyorin signs license agreement with Merck & Co. for vibegron

First phase I trial of JZP-386 begins

Teva acquires Labrys and enhances migraine portfolio

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Pharma industry faces long haul to get return on investment from AI
BioWorld Science
Artificial intelligence tools are springing up at multiple points along drug discovery and development, but despite the hype, as yet there is minimal return on...